Barclays
KLRS icon

Barclays’s Kalaris Therapeutics KLRS Stock Holding History

Barclays’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49 Sell
17
-286
-94% -$1.11K ﹤0.01% 5084
2026
Q2 		$1.23K Sell
303
-4,977
-94% -$25.8K ﹤0.01% 4914
2026
Q1 		$30.5K Sell
5,280
-785
-13% -$6.97K ﹤0.01% 4471
2025
Q4 		$51.2K Buy
+6,065
New +$38.8K ﹤0.01% 4738
2025
Q2 		– Sell
-1
Closed -$8 – 5639
2025
Q1 		$8 Buy
+1
New +$10 ﹤0.01% 5185
2024
Q2 		– Sell
-1,532
Closed -$26.6K – 5392
2024
Q1 		$26.6K Sell
1,532
-1,496
-49% -$24.4K ﹤0.01% 4721
2023
Q4 		$47.3K Buy
3,028
+2,219
+274% +$87.5K ﹤0.01% 4781
2023
Q3 		$40K Buy
809
+2
+0.2% +$136 ﹤0.01% 3956
2023
Q2 		$63.1K Sell
807
-742
-48% -$70.5K ﹤0.01% 3741
2023
Q1 		$140K Buy
1,549
+323
+26% +$41.1K ﹤0.01% 3990
2022
Q4 		$145K Buy
1,226
+305
+33% +$51.7K ﹤0.01% 4016
2022
Q3 		$167K Sell
921
-2,358
-72% -$367K ﹤0.01% 3304
2022
Q2 		$294K Buy
3,279
+2,435
+289% +$255K ﹤0.01% 3209
2022
Q1 		$131K Buy
+844
New +$168K ﹤0.01% 3665

Other funds holding KLRS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
WealthTrust Asset Management
WealthTrust Asset Management Destin, Florida $181M AUM 17.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Strengthening Families & Communities LLC
Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's KLRS Position: Q3 2026 in Review

Barclays reduced its Kalaris Therapeutics (KLRS) stake by 94% in Q3 2026, selling an estimated $1.11K and leaving 17 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #5084.

Barclays first reported a position in KLRS in Q1 2022 and has held it in 14 quarters since. The position peaked at $294K in Q2 2022. 8 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Barclays held 17 shares of Kalaris Therapeutics worth $49 as of Q3 2026.
  • Barclays sold 286 Kalaris Therapeutics shares in Q3 2026, an estimated $1.11K.
  • Kalaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5084 holding.
  • Barclays first reported a position in Kalaris Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Barclays's Kalaris Therapeutics position peaked at $294K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.